Bluebird Bio, Inc. Suspends Clinical Trial of Sickle Cell Gene Therapy: Two Subjects Develop Cancer, <i>etc</i>

doi:10.3971/j.issn.1000-8578.2021.03.0001

Bluebird Bio, Inc. Suspends Clinical Trial of Sickle Cell Gene Therapy: Two Subjects Develop Cancer, etc[J]. Cancer Research on Prevention and Treatment, 2021, 48(3): 319-320. DOI: 10.3971/j.issn.1000-8578.2021.03.0001

Citation:

Bluebird Bio, Inc. Suspends Clinical Trial of Sickle Cell Gene Therapy: Two Subjects Develop Cancer, etc[J]. Cancer Research on Prevention and Treatment, 2021, 48(3): 319-320. DOI: 10.3971/j.issn.1000-8578.2021.03.0001

Citation:

Bluebird Bio, Inc. Suspends Clinical Trial of Sickle Cell Gene Therapy: Two Subjects Develop Cancer, etc[J]. Cancer Research on Prevention and Treatment, 2021, 48(3): 319-320. DOI: 10.3971/j.issn.1000-8578.2021.03.0001

Bluebird Bio, Inc. Suspends Clinical Trial of Sickle Cell Gene Therapy: Two Subjects Develop Cancer, etc

Abstract

FullText(HTML)

References (0)

Bluebird Bio, Inc. Suspends Clinical Trial of Sickle Cell Gene Therapy: Two Subjects Develop Cancer, etc

Catalog

Export File

Citation

Format

Content